Fingolimod for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests if the drug fingolimod can help people with advanced non-small cell or small cell lung cancer that has worsened after at least two previous treatments. Fingolimod is a pill taken daily that may help the immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced non-small cell or small cell lung cancer that has grown despite at least two prior treatments.
- You are 18 years or older and can take oral medication.
- Your cancer can be measured by CT scans or other imaging tests (RECIST 1.1).
- You have a good enough activity level to be up and about at least part of the day (ECOG 0-2).
- You have not had a serious heart event (like heart attack or stroke) in the last 6 months, and you do not have certain heart rhythm problems or long QT syndrome.
- You are not pregnant, and you agree to use effective birth control during and for 2 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a new combination of two drugs (Adibelimab and Famitinib) plus chemotherapy for people with advanced non-small cell lung cancer whose previous immunotherapy (PD-1 inhibitor) has stopped working. The goal is to see if this new combination can help control the cancer when the first treatment fails.
This study tests a new medicine called PF-08634404 (an antibody-drug conjugate that targets cancer cells) combined with other anti-cancer drugs in people with advanced non-small cell lung cancer. It aims to see if these combinations are safe and effective. You may be eligible if your cancer has not responded to prior treatments or if you have not received any systemic treatment for advanced disease.
This trial tests a combination of two drugs for people with advanced non-small cell lung cancer. The drugs aim to help your immune system fight the cancer more effectively.
This trial tests a new drug (ES102) combined with an immunotherapy (Toripalimab) for people with advanced non-small cell lung cancer that has stopped responding to standard treatments. It may help those whose tumors have high PD-L1 levels.
This trial tests a new drug, PF-08634404, alone or with other treatments, for people with early-stage or locally advanced non-small cell lung cancer (NSCLC) that can be surgically removed or has been treated with radiation and chemo. It aims to find if the drug helps before or after surgery or after standard treatments.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.